Spelling suggestions: "subject:"arthritis, relatedcomplications"" "subject:"arthritis, threateningcomplications""
1 |
Rheumatologists' perceptions of the co-incidence of tuberculosis associated with TNF-a inhibitors used for the treatment of rheumatoid arthritis in South Africa.Leong, Trudy D 28 March 2014 (has links)
Biological disease-modifying anti-rheumatic drugs (DMARDs) for the treatment of
Rheumatoid Arthritis, particularly TNF-α inhibitors, have been shown to improve patient
outcome by slowing or halting radiographic damage. However, similar to most immunemodulators,
there is an increased risk of infections co-incident with Tumour necrosis factor
(TNF)-α inhibitor use, particularly the risk of activated latent tuberculosis infection (LTBI).
Therefore, local and international guidelines recommend pre-screening for tuberculosis (TB)
prior to the initiation of TNF-α therapy in rheumatoid arthritis (RA) patients. Also of critical
importance in South Africa is the need for clinicians to be aware of environmental risk
factors such as TB being highly endemic.
Thus, a qualitative analysis was performed to investigate rheumatologists’ perceptions of TB co-incident with TNF-α inhibitors.
Method: Physicians (n=18) practising rheumatology in the private and public healthcare
sectors in Gauteng were interviewed to obtain their perceptions and attitudes related to TB
co-incident with TNF-α inhibitor use. Interviews were audio-recorded and the transcripts
analysed using thematic content analysis.
Results: The determinants of health equity: Affordability, accessibility and availability of
medicines (specifically TNF-α inhibitors) was reported to be different for the public care
versus the private care patient. The high cost of TNF-α inhibitors warranted funding predominantly by the private medical schemes. A higher occurrence of latent TB infection was reported by physicians practising in the
public or combined practice compared to the occurrence of LTBI in the private sector
(21.4%versus 1.5%).
The majority of study participants advocated pre-screening of TB, prior to the initiation of
TNF-α inhibitors, in RA. However, it was suggested that because of the high occurrence of
LTBI in the public sector, Isoniazid preventative therapy (IPT) should be compulsory,
irrespective of the patient’s TB status, for the duration of TNF-α therapy.
Most study participants supported local South African Rheumatism and Arthritis Association
(SARAA) guideline recommendation to re-screen for TB by chest x-ray (CXR), every 6
months. However, the value of re-screening using diagnostic tools, purified protein
derivative (PPD) skin test or interferon-gamma release assays (IGRAs) was queried due to
the possibility of false readings.
The occurrence of associated active TB in RA patients on TNF-α inhibitors was reported to be 0.07% in the private or combined practice versus 3.00% in the public sector. Forty
percent of TB cases were reported to be extra-pulmonary. Despite active vigilance, some
physicians reported that active TB month occurred months after the cessation of TNF-α
inhibitor therapy. [Similar findings were observed from the British Society for Rheumatology
Biologics Register (BSRBR)].
The majority of patients that developed TB co-incident with TNF-α inhibitors were treated
successfully with TB chemotherapy. Only 1 of 12 patients died of extra-pulmonary TB, following compassionate use of infliximab in public care.
Conclusion: Physicians practising rheumatology in Gauteng were of the opinion that there is
a TB risk associated with the use of TNF-α inhibitors for the management of rheumatoid
arthritis, as South Africa is a TB endemic country. Most acknowledged that these biological
DMARDs were efficacious in slowing or halting radiographic progression in rheumatoid
arthritis, but emphasised the need to take steps to prevent TB reactivation in the immuno -
compromised RA patients and to remain overtly vigilant for active TB.
In clinical practice, physicians mentioned that the monitoring and management of TB
associated with TNF-α inhibitors appears to follow the socio-economic status of the RA
patient and that distinct recommendations should be made for the public healthcare as well
as the private healthcare sectors.
Different opinions emanated from different physicians relating to the adequacy of local
SARAA guidelines for the prevention of TB associated with TNF-α inhibitors. Some physicians mentioned that local guidelines were sufficient, whilst other physicians mentioned that the
diagnostic tools were inadequate in the South African setting and that additional
precautions should be taken in the form of IPT for the full duration of TNF-α therapy for all
candidates, irrespective of TB status determined during pre-screening.
As the science of biological DMARDs evolves with the rapid development of new medicinal
therapies, physicians showed a preference to consider alternative non TNF-α biological
DMARDs that had a lower risk of associated TB, specifically in high-risk RA patients. Physicians’ overall perception of the management of RA with TNF-α inhibitor therapy was
that the risk-benefit assessment of these interventions, as well as patient preference and
economic considerations should be taken into account.
|
2 |
Osteoporosis in rheumatoid arthritisKalla, Asgar Ali 08 May 2017 (has links)
The literature is replete with reports of osteoporosis in rheumatoid arthritis, but the mechanism of bone loss remains obscure. This is probably due to the overlap with bone loss of aging and the menopause, whose exact mechanisms are also poorly understood. Against this background, a study was designed to evaluate generalised bone loss in young, premenopausal (if female), patients with rheumatoid arthritis. The protocol was designed to record demographic data, as well as information pertaining to the disease. Cortical bone mass was measured at the metacarpals and left femur, using an automated, computer-controlled technique. Trabecular bone was evaluated at the left femur (Singh index) as well as at the 3rd lumbar vertebra (Saville index). Bone kinetics were studied by the measurement of urinary excretion of calcium, phosphate and hydroxy-praline (resorption) and serum alkaline phosphatase (formation). Disease activity was measured clinically and with laboratory indices. Physical activity was indirectly measured by quantitating the disability, using the Keitel function test as well as a modified health assessment questionnaire (HAQ). The radiograph of the right wrist was scored by the Larsen index. The carpometacarpal ratio was also calculated from the radiograph. Numerous statistical techniques were applied in the analysis of the data. Healthy volunteers were used as controls. Patients with SLE were also studied, in order to compare the 2 inflammatory diseases. Patients with RA had generalised cortical bone loss (metacarpal and femur) (p < 0.001). Trabecular bone measurements were not significantly different from normals, using the crude radiographic techniques. Duration of disease was the most important clinical determinant of this bone loss. The relative contributions of disease activity and lack of physical activity to the loss of bone could not be adequately separated using conventional statistical techniques. Corticosteroid therapy did not promote metacarpal bone loss in these subjects, but may have contributed to thinning of the femoral cortex. Nonsteroidal anti-inflammatory drugs and disease modifying agents did not seem to influence the extent of the bone loss. Nutritional status and skinfold thickness did not correlate with bone mass. Dietary factors played no role in the genesis of bone loss, but may have had some effect on disease activity. Metacarpal measurements showed a sensitivity of 80% and specificity of 85% in discriminating between osteopaenic and normopaenic groups with RA. Osteopaenia could not be adequately predicted in the absence of metacarpal measurements. Metacarpal bone loss in RA was due to endosteal resorption, while in SLE it was due to periosteal resorption. The semi-automatic technique for measurement of metacarpal bone mass showed good reproducibility among 5 observers and at 2 different centres. The pathogenesis of bone loss in RA was multifactorial, the largest contribution probably coming from a humoral factor in the circulation, closely related to disease activity. Ionised calcium was elevated in 55% of RA patients, but only 5% of SLE patients. Serum PTH levels were normal in 99% of the RA subjects. Elevations in alkaline phosphatase. (25%) probably reflected disease activity rather than increased bone formation. Factor analysis of 27 variables showed that disease activity was central to the development of OP in RA. CS therapy tended to be used in the presence of active disease. Disability was not an important determinant of bone loss in RA, but may be a useful measure of activity of the disease. This study did not evaluate the relationships with sex hormonal status or vitamin D metabolism. Future research should aim at cohort analysis at 2 different periods, in order to improve our understanding of the pathogenesis of bone loss in RA.
|
Page generated in 0.2096 seconds